Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study tracks Selumetinib's impact on NF1 tumors in children

NCT ID NCT05891847

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on treatment, and any side effects. The goal is to see how selumetinib works in everyday medical practice in Russia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
selumetinib
What this could lead to
If successful, this study could confirm that selumetinib effectively shrinks or stabilizes these tumors in children with NF1 outside of controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be less reliable. Selumetinib can cause side effects like nausea, diarrhea, and skin issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

Mar 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population will consist of pediatric patients aged 3 years and older with NF1 and symptomatic inoperable PN who were prescribed with selumetinib

Ages

3 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * NF1 diagnosed (according to the criteria for evaluating NF1), * Symptomatic inoperable PN, * Patients receiving therapy with selumetinib. For newly treated patients - registration on the first day of starting treatment with selumetinib, * Age at starting of selumetinib treatment ≥ 3 to ≤ 18 years old (included in the study or started the therapy at the age of 18 years old), * Patients whose parents or guardians have signed a consent form. Exclusion Criteria: * Patients currently participating in an interventional study/clinical trial, * Patients are excluded if there is evidence of an optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer, requiring treatment with chemotherapy or radiation therapy, * Patients who receive other antitumor treatment options on optic nerve glioma, malignant glioma, malignant tumor of the peripheral nerve sheath, or other cancer. If the patient on selumetinib treatment develop optic nerve glioma, malignant glioma, malignant tumor of the peripheral nerve sheath, or other cancer, he can continue selumetinib therapy +\\- other treatment options on physician decision, * Female patients above 12 age who are pregnant /plan to become pregnant or at breast feeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurofibroma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibroma neurofibromatosis type 1 plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neurofibroma

Contacts and locations

Locations

  • Research Site

    Moscow, Moscow, 123112, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.